stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) EBITDA
Viridian Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$369.7M, compared with −$314.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$474.6M. Over the past ten years it has ranged from −$369.7M (fiscal 2025) to −$11.0M (fiscal 2015) — the current reading is the lowest in ten years. EBITDA has fallen for 4 consecutive fiscal years. Viridian Therapeutics, Inc. ranks 574th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$369.7M | — |
| FY2024 | −$314.2M | — |
| FY2023 | −$265.4M | — |
| FY2022 | −$134.3M | — |
| FY2021 | −$78.6M | — |
| FY2020 | −$109.8M | — |
| FY2019 | −$42.1M | — |
| FY2018 | −$33.2M | — |
| FY2017 | −$26.2M | — |
| FY2016 | −$16.6M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$104.7M | — |
| Jun 2026 | −$127.6M | — |
| Mar 2026 | −$117.9M | — |
| Dec 2025 | −$124.4M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | −$123.8M |
| CELC Celcuity, Inc. compare | −$204.0M |
| IDYA IDEAYA Biosciences, Inc. compare | −$463.5M |
| VRDN Viridian Therapeutics, Inc. | −$474.6M |
| DNLI Denali Therapeutics Inc. compare | −$524.5M |
| DYN Dyne Therapeutics, Inc. compare | −$536.1M |
| VKTX Viking Therapeutics, Inc. compare | −$652.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$695.5M |
| TLX Telix Pharmaceuticals Limited compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement